EP0804550A4 - Die ex vivo aktivierung von immunzellen - Google Patents

Die ex vivo aktivierung von immunzellen

Info

Publication number
EP0804550A4
EP0804550A4 EP95906781A EP95906781A EP0804550A4 EP 0804550 A4 EP0804550 A4 EP 0804550A4 EP 95906781 A EP95906781 A EP 95906781A EP 95906781 A EP95906781 A EP 95906781A EP 0804550 A4 EP0804550 A4 EP 0804550A4
Authority
EP
European Patent Office
Prior art keywords
immune cells
vivo activation
vivo
activation
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95906781A
Other languages
English (en)
French (fr)
Other versions
EP0804550A1 (de
Inventor
Bruce P Babbitt
Zhengyi J Zhang
Michael E Osband
Joseph James Goodman
Barry Inn Caplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellcor Inc
Original Assignee
Cellcor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/214,400 external-priority patent/US5569585A/en
Application filed by Cellcor Inc filed Critical Cellcor Inc
Publication of EP0804550A1 publication Critical patent/EP0804550A1/de
Publication of EP0804550A4 publication Critical patent/EP0804550A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP95906781A 1994-01-27 1995-01-06 Die ex vivo aktivierung von immunzellen Withdrawn EP0804550A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18826294A 1994-01-27 1994-01-27
US188262 1994-01-27
US08/214,400 US5569585A (en) 1993-03-12 1994-03-16 In vitro assay measuring degree of activation of immune cells
US214400 1994-03-16
US30098294A 1994-09-06 1994-09-06
US300982 1994-09-06
PCT/US1995/000193 WO1995020649A1 (en) 1994-01-27 1995-01-06 Ex vivo activation of immune cells

Publications (2)

Publication Number Publication Date
EP0804550A1 EP0804550A1 (de) 1997-11-05
EP0804550A4 true EP0804550A4 (de) 1998-08-05

Family

ID=27392383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95906781A Withdrawn EP0804550A4 (de) 1994-01-27 1995-01-06 Die ex vivo aktivierung von immunzellen

Country Status (3)

Country Link
EP (1) EP0804550A4 (de)
AU (1) AU1524095A (de)
WO (1) WO1995020649A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
PT768886E (pt) * 1995-05-05 2003-12-31 Vasogen Ireland Ltd Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
DE19814701A1 (de) * 1998-04-01 1999-10-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von mit dem Gehirn assoziierten Erkrankungen, Störungen und Schädigungen
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017567A1 (en) * 1991-04-05 1992-10-15 Regents Of The University Of Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
WO1993000918A1 (en) * 1991-07-10 1993-01-21 Ochoa Augusto C Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017567A1 (en) * 1991-04-05 1992-10-15 Regents Of The University Of Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
WO1993000918A1 (en) * 1991-07-10 1993-01-21 Ochoa Augusto C Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOLD J E ET AL: "Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: Effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 73 (1). 1994. 115-122, XP002066053 *
GOLD J E ET AL: "Autolymphocyte therapy: II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 71 (3). 1994. 325-332, XP002066054 *
ROSS S.D. ET AL.: "Autolymphocytes therapy (ALT) for disseminated melanoma: results in a pilot study of 26 patients", PROC ANN MEET AM SOC CLIN ONCOL, vol. 12, March 1993 (1993-03-01), pages a1326, XP002066052 *
See also references of WO9520649A1 *

Also Published As

Publication number Publication date
WO1995020649A1 (en) 1995-08-03
AU1524095A (en) 1995-08-15
EP0804550A1 (de) 1997-11-05

Similar Documents

Publication Publication Date Title
PL328822A1 (en) Human bikinine
EP0793501A4 (de) 'in vivo'aktivierung von tumorspezifischen-zytotoxischen t-zellen
GB2301538B (en) Prosthesis assembly
EP0804550A4 (de) Die ex vivo aktivierung von immunzellen
HU9700071D0 (en) Use of muramilpeptides
AU125644S (en) Capsule
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
GB9602704D0 (en) Structure of perculator
EP0797592A4 (de) Menschliches stanniocalcin-alpha
NZ295530A (en) Preparation of 1-halo-3-trialkylsilanyl-benzenes
ZA947865B (en) Human glactokinase
TW315835U (en) Novel can body
EP0795006A4 (de) MENSCHLICHES MuT2
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
GB2312677B (en) Medicament comprising undifferentiated cells
HU9502355D0 (en) Human interleukin-6-inhibitor
ZA949714B (en) Human MutT2
GB9422523D0 (en) Human cell lines
GB9414971D0 (en) Preparation of thionucleosides
GB9412984D0 (en) Methods of diagnosis
AU120784S (en) Heart pendant
PL303018A1 (en) Artificial valvule
GB9514341D0 (en) Artificial ski-slopes
AU128021S (en) Lipstick
TW304520U (en) Improved structure of groyne

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960827

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 19980619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE ES FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990803